Quotables
"The idea that cavalry will be replaced by these iron coaches is absurd. It is little short of treasonous."
Aide-de-camp to Field Marshal Haig ; At a tank demonstration, 1916
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110268762 | IMMUNIZATION OF AVIANS BY MUCOSAL ADMINISTRATION OF NON-REPLICATING VECTORED VACCINES The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant hum... | 11/03/2011 |
| 20110268764 | IMMUNE RESPONSE INDUCING PREPARATIONS The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or ... | 11/03/2011 |
| 20110236419 | RECOMBINANT CDV COMPOSITIONS AND USES THEREOF The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. T... | 09/29/2011 |
| 20110212123 | Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least ... | 09/01/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110171261 | IMMUNOGENIC COMPOSITION This invention relates to the use of a CCR4 antagonist as an adjuvant, in particular in an immunogenic composition comprising an antigen which elicits an immune response against a pathogen or tumour.... | 07/14/2011 |
| 20110150940 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or... | 06/23/2011 |
| 20110135679 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a... | 06/09/2011 |
| 20110033549 | Stabilisation of Proteins A dry composition for use in therapy or diagnosis, obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, wherein the pH of the aqueous composition is such that the protein is stable, wherein the or each displacement buffe... | 02/10/2011 |
| 20100310656 | Immunotherapy and prevention of autoimmune hepatitis The invention is within the field of immunology and microbiology, more specifically the field of virology and is related to immunotherapy and prophylaxis of hepatitis and autoimmune diseases. The composition useful for these purposes is disclosed, including the methods ... | 12/09/2010 |
| 20100285135 | Nanoparticles For Use In Immunogenic Compositions Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such composi... | 11/11/2010 |
| 20100272752 | VACCINE FOR VIRUSES THAT CAUSE PERSISTENT OR LATENT INFECTIONS The invention is in general directed to methods and compositions for preventing or treating infections by viruses involved in persistent and/or latent infections. The methods and compositions are directed toward the prevention and treatment of infections caused by virus... | 10/28/2010 |
| 20100255030 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of th... | 10/07/2010 |
| 20100247537 | ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is als... | 09/30/2010 |
| 20100239608 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitabl... | 09/23/2010 |
| 20100158948 | ADAPTIVE MUTATIONS ALLOW ESTABLISHMENT OF JFH1-BASED CELL CULTURE SYSTEMS FOR HEPATITIS C VIRUS GENOTYPE 4A The present inventors developed three 4a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 4a reference strain ED43. The 4a/2a junction in NS2 was pl... | 06/24/2010 |
| 20100150960 | COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED IMMUNE RESPONSE The present invention features methods and compositions related to chitosan antigen depots, and chitosan cytokine depots, and the use of depot compositions in treating and preventing diseases.... | 06/17/2010 |
| 20100136043 | COMPOSITION COMPRISING IMMUNOGENIC MICROPARTICLES The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting ... | 06/03/2010 |
| 20100112078 | POLYMER PARTICLES BASED VACCINE The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wher... | 05/06/2010 |
| 20090324643 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTION This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample... | 12/31/2009 |
| 20090263421 | CELLULAR VACCINE The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nuc... | 10/22/2009 |
| 20090226489 | VIRAL VACCINE COMPOSITION, PROCESS AND METHODS OF USE A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically ab... | 09/10/2009 |
| 20090123495 | Immune Response Inducing Preparations The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or ... | 05/14/2009 |
| 20090047348 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF A biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances are provided.... | 02/19/2009 |
| 20090041852 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or... | 02/12/2009 |
| 20090022683 | Biodegradable and Thermosensitive Poly(Organophosphazene) Hydrogel, Preparation Method Thereof and Use Thereof The present invention relates to a biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances. According to the present invention, poly(organophosphazene) is a p... | 01/22/2009 |
| 20080267997 | Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs so... | 10/30/2008 |
| 20080233149 | Use of Erythropoietin for Enhancing Immune Responses and for Treatment of Lymphoproliferative Disorders The present invention relates to the use of erythropoietin (EPO) for enhancing immune responses and for the treatment of lymphoproliferative disorders, excluding multiple myeloma. Accordingly to the invention EPO may be administered with a viral or bacterial vaccine.... | 09/25/2008 |
